To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Brielle Benyon
An expert discusses the current landscape – as well as future prospects – for immunotherapy in lung cancer.
Beth Fand Incollingo
Immunotherapy has become a buzzword in the cancer community, but to Sean Parker it’s much more. The 39-year-old billionaire is intensely focused on the promise of immunotherapy, and has become a major force in helping to drive its potential to cure cancers.
Beth Fand Incollingo
A retrospective study found that clinical trials may have fewer reported side effects than the real world.
Jessica Skarzynski and Kristie L. Kahl
While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.
Katie Kosko
Although immunotherapies show promise for patients, there are still challenges ahead.
Brielle Urciuoli
Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.
Katie Kosko
The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.
Jason Harris
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
Angelica Welch
After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?
Brielle Urciuoli
While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other